1-3 of 3
Anna D.D. van Muyden
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5101) in Relapsed/Refractory NHL: Results from the Phase 1 Atalanta-1 Trial

Marie José Kersten, Kirsten Saevels, Yves Beguin, Joost S.P Vermaat, Nadia Verbruggen, Maike Spoon, Marte C. Liefaard, Margot Pont, Anna D.D. van Muyden, Maria T. Kuipers, Sébastien Anguille
Journal: Blood
Blood (2023) 142 (Supplement 1): 2113.
https://doi.org/10.1182/blood-2023-172736
Published: 2023
Journal Articles

Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5201) in Relapsed/Refractory CLL/SLL Including Richter's Transformation: Results from the Phase 1 Euplagia-1 Trial

Natalia Tovar, Valentin Ortiz-Maldonado, Nuria Martinez-Cibrian, Sergi Betriu, Daniel Esteban, Ana Triguero, Nadia Verbruggen, Maike Spoon, Marte C. Liefaard, Margot Pont, Anna D.D. van Muyden
Journal: Blood
Blood (2023) 142 (Supplement 1): 2112.
https://doi.org/10.1182/blood-2023-189321
Published: 2023
Journal Articles

Rationale for and Design of Papilio-1: A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Feasibility, Safety, and Efficacy of Point-of-Care-Manufactured Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells (GLPG5301) in Relapsed/Refractory Multiple Myeloma

Niels W.C.J. van de Donk, Sébastien Anguille, Jo Caers, Marte C. Liefaard, Christian Jacques, Anna D.D. van Muyden
Journal: Blood
Blood (2023) 142 (Supplement 1): 4859.
https://doi.org/10.1182/blood-2023-189001
Published: 2023